This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2018 Oct 9;138(15):1534-1536.

doi: 10.1161/CIRCULATIONAHA.118.036449.

Apixaban for End-Stage Kidney Disease

Elaine M Hylek¹

Affiliations

PMID: 30354524
DOI: 10.1161/CIRCULATIONAHA.118.036449

Editorial

Apixaban for End-Stage Kidney Disease

Elaine M Hylek. Circulation. 2018.

. 2018 Oct 9;138(15):1534-1536.

doi: 10.1161/CIRCULATIONAHA.118.036449.

Author

Elaine M Hylek¹

Affiliation

¹ Boston University School of Medicine, MA.

PMID: 30354524
DOI: 10.1161/CIRCULATIONAHA.118.036449

No abstract available

Keywords: Editorials; anticoagulation; atrial fibrillation; dialysis; stroke prevention.

PubMed Disclaimer

Comment on

Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States.
Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, Tilea A, Stack AG, Balkrishnan R, Yao X, Noseworthy PA, Shah ND, Saran R, Nallamothu BK. Siontis KC, et al. Circulation. 2018 Oct 9;138(15):1519-1529. doi: 10.1161/CIRCULATIONAHA.118.035418. Circulation. 2018. PMID: 29954737 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information